Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This study suggests that the developed PBPK model effectively predicts pharmacokinetic and pharmacodynamic profiles of topical finasteride and minoxidil on the scalp, indicating potential broader applicability for other formulations.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

In this study, researchers found that among healthy Korean males, the clearance of finasteride was about 34% lower in individuals with the CYP3A5*3 homozygous allele compared to other genotypes, suggesting dosage adjustments may be necessary considering CYP3A5 and ALT levels to avoid adverse effects.

This study models the pathways of nandrolone and its metabolites in the body and suggests methods to counteract finasteride's role in enabling PED users to cheat drug tests.

This database provides detailed physiological parameters of porcine skin to enhance the MPML MechDermA Model, improving dermal absorption predictions for human studies in the Simcyp Simulator.

This study demonstrated that finasteride-loaded PLGA microspheres created using a novel microfluidic device exhibit extended drug release in beagle dogs, with modifications allowing for release up to 3 months.

This study found that hair follicles contribute significantly to caffeine absorption shortly after topical application, with a faster absorption rate compared to the stratum corneum.

This study found that while nicotinic acid significantly inhibited human sebaceous organoid growth in vitro, the predicted skin concentrations from gut microbiome-derived levels were far below the effective dose, suggesting high oral doses would be necessary for therapeutic effects.

This review explores the potential use of plucked hair follicles in regenerative medicine and diagnostics but presents no new research findings.

This source presents the Drug Database for Hair Loss Disorders, offering comprehensive details about pharmacological agents for treating hair loss conditions, including information on chemical properties, efficacy, and safety, aimed at supporting research and drug development.

This study introduced the Drug Database for Hair Loss Disorders, which provides comprehensive details on pharmacological agents used to treat hair loss conditions, aiding research and development efforts in drug companies through accessible chemical properties, mechanisms, and efficacy data.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This review discusses the role of skin enzymes in drug metabolism and emphasizes the need for models assessing enzyme activity to evaluate the safety and bioequivalence of topical generic drugs, highlighting efforts to standardize testing protocols for transdermal products.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

This study explored the wound healing potential of a natural marine soft coral-derived nanoparticle-based gel in a diabetic excision wound model, finding it effectively regulates proinflammatory cytokines and inhibits enzymes related to wound healing.

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

In this study, the administration of indole-based compounds, particularly L-Tryptophan and Tryptophol, to a PCOS-induced rat model resulted in an increased number of healthy ovarian follicles and a reduction in ovarian cysts compared to untreated rats, suggesting potential therapeutic efficacy.